Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea · Delayed Price · Currency is KRW 1,629,000
-28,000 (-1.69%)
Last updated: Mar 12, 2026, 12:30 PM KST
Samsung Biologics Revenue
In the year 2025, Samsung Biologics had annual revenue of 4.56T KRW with 30.31% growth. Samsung Biologics had revenue of 1.29T in the quarter ending December 31, 2025.
Revenue
4.56T
Revenue Growth
+30.31%
P/S Ratio
16.83
Revenue / Employee
955.34M
Employees
4,770
Market Cap
76.70T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.56T | 1.06T | 30.31% |
| Dec 31, 2024 | 3.50T | -197.44B | -5.34% |
| Dec 31, 2023 | 3.69T | 693.29B | 23.10% |
| Dec 31, 2022 | 3.00T | 1.43T | 91.41% |
| Dec 31, 2021 | 1.57T | 403.23B | 34.62% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celltrion | 3.90T |
| SK Biopharmaceuticals | 675.41B |
| SK bioscience | 624.03B |
| PharmaResearch | 496.03B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |
| HLB Co., Ltd. | 80.73B |
| OliX Pharmaceuticals | 10.18B |
Samsung Biologics News
- 1 day ago - Samsung Biologics Teams Up With Eli Lilly To Establish Lilly Gateway Labs Site In Korea - Nasdaq
- 7 weeks ago - Samsung BioLogics Co Ltd (XKRX:207940) Q4 2026 Earnings Report Preview: What To Look For - GuruFocus
- 2 months ago - Samsung Biologics Expands U.S. Presence with $280M Acquisition - GuruFocus
- 2 months ago - Samsung Biologics To Acquire GSK's Rockville Facility For US$280 Mln - Nasdaq
- 2 months ago - Samsung Biologics to Acquire Human Genome Sciences from GSK - GuruFocus
- 4 months ago - Samsung BioLogics Co Ltd (XKRX:207940) Q3 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
- 5 months ago - Korean Stock Market Declines Amid Trade Uncertainty; Samsung Biologics (SSNLF) Drops - GuruFocus
- 5 months ago - Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal - The Times of India